CYTOKINETICS, INCORPORATED Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
CYTOKINETICS, INCORPORATED (CYTK) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $2.46 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-02-26
- CYTOKINETICS, INCORPORATED share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-09-30 was $720.00K.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-06-30 was $514.00K.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2024-03-31 was $18.45M, a 75.42% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2023-03-31 was $10.52M, a 9.53% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $2.46M, a 87.49% decline from fiscal 2024.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $19.63M, a 86.66% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $10.52M, a 9.53% increase from fiscal 2022.
- CYTOKINETICS, INCORPORATED share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $9.60M, a 115.82% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.46M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $720.00K 10-Q · filed 2025-11-05 | $1.23M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2025-06-30 | $514.00K 10-Q · filed 2025-11-05 | |||
| 2024-12-31 | $19.63M 10-K · filed 2026-02-26 | |||
| 2024-03-31 | $18.45M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $10.52M 10-K · filed 2026-02-26 | |||
| 2023-03-31 | $10.52M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $9.60M 10-K · filed 2025-02-27 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-11-04 | $9.60M derived: sum of 2 quarters · filed 2023-11-03 | ||
| 2022-03-31 | $9.60M 10-Q · filed 2023-11-03 | |||
| 2021-12-31 | $4.45M 10-K · filed 2024-02-28 | |||
| 2021-03-31 | $4.45M 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | $2.25M 10-K · filed 2023-03-01 | |||
| 2020-03-31 | $2.25M 10-Q · filed 2021-11-05 | |||
| 2019-12-31 | $732.00K 10-K · filed 2022-02-25 | |||
| 2019-03-31 | $732.00K 10-Q · filed 2020-11-06 | $732.00K derived: sum of 2 quarters · filed 2021-02-26 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $866.00K 10-K · filed 2021-02-26 | ||
| 2018-09-30 | $866.00K 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $0.00 10-Q · filed 2019-11-01 | $866.00K derived: sum of 2 quarters · filed 2019-11-01 | ||
| 2018-03-31 | $866.00K 10-Q · filed 2019-11-01 | |||
| 2017-12-31 | $904.00K 10-K · filed 2019-03-07 | |||
| 2016-12-31 | $135.00K 10-K · filed 2018-03-05 | |||
| 2015-12-31 | $144.00K 10-K · filed 2018-03-05 | |||
| 2014-12-31 | $96.00K 10-K · filed 2017-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |